The Future Role of Anti???Tumour Necrosis Factor-?? Products in the Treatment of Crohn??s Disease

This publication has 21 references indexed in Scilit:

• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
  New England Journal of Medicine, 1997
• Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein
  New England Journal of Medicine, 1997
• Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?
  Trends in Pharmacological Sciences, 1997
• Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease
  The Lancet, 1997
• Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.
  1996
• The basis of current and future therapy for inflammatory bowel disease
  The American Journal of Medicine, 1996
• Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
  New England Journal of Medicine, 1996
• Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor .alpha. induced receptor aggregation
  Biochemistry, 1992
• 2 DIFFERENT CELL-TYPES HAVE DIFFERENT MAJOR RECEPTORS FOR HUMAN-TUMOR NECROSIS FACTOR (TNF-ALPHA)
  1989
• The active form of tumor necrosis factor is a trimer.
  Journal of Biological Chemistry, 1987